US Delivery Delivery, Kanada Kasuwancin Gida, Bayar da Harshen Turai

Buparlisib (944396-07-0)

Rating:
5.00 daga 5 bisa 1 abokin ciniki rating
SKU: 944396-07-0. category:

AASraw yana tare da kira da kuma samar da samfurin daga gram zuwa umurnin taro na Buparlisib (CAS 944396-07-0), a ƙarƙashin tsarin CGMP da tsarin kula da kyawawan dabi'u.

Buparlisib foda abu ne mai mahimmanci, wanda ba shi da samuwa, mai mahimmanci, kuma mai yiwuwar mai hana gidan I phosphatidylinositol 3-kinase (PI3K) iyali, da kuma matsayinsa na wakili na anticancer a halin yanzu an gudanar da bincike.

AASRAW foda PDF Icon

Samfur Description

Buparlisib bidiyo


Yankin Buparlisib na asali

name: Buparlisib
CAS: 944396-07-0
Kwayoyin Formula: C18H21F3N6O2
Girman kwayoyin halitta: 410.3935496
Shawarwar Melt: 645.7 ± 65.0 ° C
Ajiye Temp: -20 ° C
Color: White crystalline foda


Buparlisib (944396-07-0) amfani da shi a yanayin zagaye na steroid

names

Buparlisib (944396-07-0), wani magunguna na I phosphotidyinositol-3-kinase (PI3K).

Ciwon ƙwayar cutar ciwon ciki

① Bayani

Buparlisib wani nau'i ne na I phosphotidyinositol-3-kinase (PI3K). A halin yanzu na nazarin nazarin lafiyar, pharmacokinetics, da kuma inganci na buparlisib tare da capecitabine a cikin marasa lafiya da ciwon daji na ciwon ciki.

② Abokan lafiya da hanyoyi
Marasa lafiya sun karbi buparlisib sau daya (rana, 50 zuwa 100 MG) don 3 makonni tare da capecitabine sau biyu (rana, 1000 zuwa 1250 mg / m2) don makon 2 tare da hutu na 1-week. Ƙarƙasawar ƙyama ta yi amfani da tsarin "3 + 3" na al'ada da ma'anoni masu mahimmanci na maye gurbin ƙananan ƙwayoyin cuta (DLT) da kuma matsakaicin iyakar magani.

③ Sakamako
Daga 25 marasa lafiya sunaye, 23 sun kasance masu amfani ga DLT da 17 sun kasance masu amfani don amsawa. Matsakaicin matsakaicin haɗin haɗin haɗin shine buparlisib 100 MG kowace rana da kuma 1000 mg / m2 na capecitabine sau biyu a kowace rana. DLT sun haɗa da nauyin 3 na hyperglycemia da kuma rikicewar 3. Mafi yawan nau'in 3 da aka fi sani shine cututtuka da hawan aspartate aminotransferase da alanine transaminase. Ɗaya daga cikin masu haƙuri ya nuna cikakken amsa ga jiyya kuma hudu sun tabbatar da amsawar da aka yi. A cikin 3 da 4 masu nazari, wanda Buparlisib (944396-07-0) ya kasance mai ƙarfi amma an kara yawan kwayar capecitabine, yawan haɓaka a cikin ƙaddamar da plasma buparlisib an lura.

④ Ƙarewa
Haɗin buparlisib tare da capecitabine a cikin marasa lafiya da ciwon ƙwayar ƙwayar cutar ciwon ƙwayar cutar ta jiki ne da aka ba da izini sosai, tare da wasu marasa lafiya suna nuna amsoshin tsawo. An yi la'akari da ƙananan ƙananan ƙwayoyin PIK3CA (3 na 17), kuma kawai 2 na ciwon sukari na 7 tare da ƙaddamarwa sun kasance mai haske, yin bincike akan waɗannan alamar da suka fi dacewa. Ƙarin nazarin haɗuwa ba ƙari bane, tare da ƙwararriyar magungunan magani da kuma nazarin zane-zane don inganta hulɗar miyagun ƙwayoyi da miyagun ƙwayoyi da mahimman ƙaddara masu mahimmanci na amsawa.

Karin bayani

Canji na phosphatidylinositol 3-kinase (PI3K) / AKT / mammalian na hanyar alamar rapamycin shine mahimmanci ga ci gaba da ci gaba da ciwon daji, ciki har da ciwon nono. Bugu da ƙari, dysregulation na alama na PI3K zai iya taimakawa wajen jurewa da dama ga jami'in anticancer. PI3K masu hanawa na iya, sabili da haka, su zama tasiri a matsayin maganin antineoplastic. Buparlisib yana da mahimmanci mai mahimmanci mai mahimmanci na kwakwalwa na gidan PI3K. Buparlisib musamman ya hana kundin I PIK3 a cikin hanyar PI3K / AKT ta hanyar sigina a cikin hanyar ATP-m, saboda haka hana hanawar na sakandaren phosphatidylinositol (3,4,5) -trisphosphate da kuma kunna hanyar hanyar PI3K. Wannan na iya haifar da hana ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta da kuma rayuwa a cikin yawan ƙwayoyin tantanin halitta mai tsari. Buparlisib a halin yanzu an gudanar da bincike akan marasa lafiya da ciwon sukari da dama, ciki har da ciwon nono. Buparlisib an tabbatar da shi a matsayin wakili mai yardar rai, kuma an yi ƙoƙari mai girma don bunkasa shi. Duk da haka, buparlisib monotherapy ya haifar da amfani mai zurfi a yanzu. Sakamakon binciken da ke hada buparlisib tare da wakili daban-daban na anticancer - wato, endocrine farfesa, anti-HER2 farfesa, da kuma chemotherapy - sun nuna tasiri mai inganci tare da daidaitattun ƙwayar cuta.


Yadda za a sayi Buparlisib daga AASraw

1.To tuntube mu ta hanyar imel ɗinmu tsarin bincike, ko skypewakilin sabis na abokin ciniki (CSR).
2.To samar mana da tambaya da adireshinka.
3.Our CSR zai ba ka zance, lokacin biya, lambar ƙididdiga, hanyoyin bayardawa da kuma kwanan wata zuwa ranar da aka zo (ETA).
4.Bayayyar da aka yi kuma za'a fitar da kayayyaki a cikin 12 hours (Domin a cikin 10kg).
5.Goods samu da bada comments.

BATSA DA TATTAUNAWA:

Ana Samun Wannan Abubuwan ne Don Amfani da Bincike Kawai. Sharuɗɗan Siyarwa suna Aiwatarwa. Ba don Amfani da Dan Adam bane, ko Likita, dabbobi, ko Amfani na Gida.


=

COA

HNMR

Recipes

Karin bayani & amsoshin samfurin